Your chance to win a partnership with GSK—helping to develop new medicines from your innovative ideas.Fast Track

Discovery

Your idea. Our resources.Do you have a novel drug discovery concept? Are you affiliated with a European or North American college or university? Are you excited about partnering with a leading pharmaceutical company to translate your novel science into a new medicine?

A winning concept.Tell us about your concept. Our expert panel of judges will evaluate each submission, selecting up to ten winners from Europe and ten winners from North America.

If your concept is chosen, and if you choose us, GSK will collaborate with you to test the full diversity of our compound collection using our state-of-the-art screening platforms to discover active compounds. Based on the results, we will share the best chemical probes with you and, together, we’ll discover compounds for use in advanced biological assays. In short, you and your concept will be on an accelerated path to success.

For details on how you can take advantage of this opportunity, visit www.gsk.com/discoveryfasttrack

If so, the Discovery Fast Track Challenge is for you.

What are we looking for?Clear therapeutic hypothesis

A coherent and supportable hypothesis that modulation of target will produce a physiological effect which will be of therapeutic benefit to particular patients

Target defined Specific drug target identified, and some understanding of type of pharmacology desired

(Exclusive) enabling expertise

Academic partner has know-how and/or expertise essential to progressing the target which is not (readily) found elsewhere

Tractability A path to identification of a drug molecule can be defined. Target knowledge suggests that a drug-like molecule can be generated

Requirement for GSK contribution

GSK has capabilities and expertise which will help progress the project to the next milestone

Challenge

Sponsored by GlaxoSmithKline’s Discovery Partnerships with Academia (DPAc) team in association with the Platform and Technology Sciences team.

Submit your novel drug discovery concept and you could find yourself on the fast track. Up to ten winners from Europe and ten winners from North America will gain access to the experience and resources of GSK.

GSK partnerships provide world-class knowledge in lead discovery and access to our unique compound collections of highly diverse chemistry. Using our expertise in drug discovery, we will provide high-quality probes to address your biological questions.

Encoded Library Technology (ELT)

ELT is an affinity-based selection methodology for hit identification. This technology is based on the synthesis and screening of a highly diverse collection of DNA-encoded small molecules. In a simple affinity selection experiment, libraries containing billions of compounds are exposed to the target. Bound molecules are then recovered and de-convoluted using next-generation sequencing. This technology has minimal target requirements and has been successfully applied to a range of enzyme, protein-protein and receptor targets, including protein isolated from patients.

Hit Qualification SupportSelecting the optimal tool compound(s) from the hundreds or thousands of raw screening hits typically requires the use of a range of assays (e.g., biochemical, biophysical, cell-based), along with computational chemistry approaches to identify emergent structure-activity relationships. To accomplish this, GSK operates a fully integrated environment, and takes a holistic computation and experimental approach. We provide both the relevant measure-ments and the interpretational guidance, ensuring the selected compounds possess the best chemical properties and interact with the target via a desired modality.

HTSHigh Throughput Screening (HTS) enables the testing of millions of pure compounds using a diverse set of technologies in biochemical and cellular assays of different complexity. The GSK HTS chemical library consists of around 2 million compounds selected to enhance the success in finding high-quality molecules for lead optimization programs. The infrastructure in miniaturization, robotics and data analysis—together with years’ of experience—make HTS a fast and high-quality process. Results are analyzed with sophisticated chemical probe selection algorithms that include robust statistics, chemical clustering, data mining and physiochemical properties.

Enter the Discovery Fast Track Challenge for a chance to collaborate with GSK.

Reagents and Assays

Reagents and assays are customized to identify quality chemical probes. A wide range of biochemical, biophysical, cellular and phenotypic assays can be exploited and scaled to meet lead discovery needs.

Fast TrackDiscovery

Challenge

Helpful Tips for Principal InvestigatorsAbout the submission process.• Useful information about the Discovery Fast Track Challenge is available at www.gsk.com/discoveryfasttrack.

Sign up under Challenge News to receive regular updates from the GSK team.

• Initial entries into the Discovery Fast Track Challenge are made via submission of a one-page non-confidential proposal. Submissions are open from February 24 to April 23 in Europe, and from February 24 to May 16 in North America. Please try to submit your proposal as early as possible.

• Submission will not progress to the GSK review cycle until your technology transfer office (TTO) has reviewed the proposal to verify compliance with the rules of the challenge. During the online submission process, you will be asked to provide an email address for the relevant TTO.

• Ideally, the TTO should have reviewed the proposal prior to formal submission to the competition. If this step is done, then TTO approval via the GSK portal will be expedited and your proposal will advance to the review stage more quickly.

• The rules of the challenge should be reviewed and followed carefully to avoid disqualification of a submission. Visit www.gsk.com/discoveryfasttrack for details.

Points to bear in mind when considering entering the Discovery Fast Track Challenge.• Initial submissions should include only non-confidential information. If you are unsure whether the submission

contains confidential information, please contact your TTO for assistance. At this initial stage, GSK does not want to accept confidential information that must be protected or that may preclude patent protection later.

• If your proposal is selected to become a finalist, an expanded confidential proposal (~5 pages) will be required, which will be subject to an appropriate confidentiality agreement.

• Your submission(s) and any associated materials required to execute the proposed screen must be free from any third-party obligations that would prevent GSK from obtaining rights under the challenge rules and agreements. If you have questions about what obligations are associated with your proposed concept, please contact your TTO as soon as possible for assistance.

• GSK will require appropriate rights to proceed with the proposed research (e.g. High Throughput Screening). Therefore, submitting investigators will need to verify that the materials required to perform this research are not encumbered by agreements, obligations or restrictions that prevent their use for commercial purposes.

• If co-investigators helped to develop the concept outlined in the Discovery Fast Track Challenge proposal, they must agree to the submission in accordance with the challenge rules.

Continued...

www.gsk.com/discoveryfasttrack

GSK

TTOInvestigator

Four possible research outcomes:

Outcome One: GSK and institution agree to continue research under a DPAc agreement to be negotiated; likely research funding available. If no agreement, GSK can elect outcome #3.

Investigators submit online proposals

1

3 GSK notifies finalists and assigns a GSK mentor

4

Finalists submit confidential 3–5 page proposals

6 Finalists visit GSK, present proposals to judging panel

7

Outcome Two: Institution wants to continue research; GSK does not. GSK will provide chemical probes to institution under an agreement or for a (likely) joint publication.

Outcome Three: GSK wants to continue Research; Institution does not. GSK gets a license to patents claiming material in exchange for milestone payments.

Outcome Four: Neither party wants to continue research or no useful chemical probes are identified from the screen. GSK may opt to proceed at a later date after reconsideration and discussion with institution (per MTA).

Challenge opens February 24 in Europe and North America

Milestone

Milestone

Finalists will be asked to present on one of the following dates:Europe – July 7,9,10,11 (Stevenage, UK)North America – September 10,11,12, 15 (Philadelphia, USA)

MilestoneWinners announcedEurope – late-SeptemberNorth America – mid-November

Milestone

Winners notified and screening work-plans designed

9

TTOs confirm approval of proposals by institution

2 CDA signed, MTA discussed with GSK

5

GSK judges review approved proposals and select finalists

GSK judging panel selects successful proposals

8 10 MTA containing work-plans for specific proposals signed

MilestoneFinal deadline for TTO ApprovalEurope – April 30, North America – May 23

Challenge closes Europe – April 23North America – May 16

Screening begins1–2Q 2015

12 Screen outcomes reviewed

Winners announced, team of GSK scientists assigned to project

11

Registration Period & TTO

ApprovalSelection of

FinalistsFinalist

SubmissionSelection of

WinnersWinner MTAs

Signed

Winners Announced, Lab

Work Begins

Screen Outcomes Reviewed

Workflow for Discovery Fast Track ChallengeWorkflow for Discovery Fast Track Challenge

Fast TrackDiscovery

Challenge

One-page non-confidential proposals accepted until April 23 in Europe and May 16 in North America.Go to www.gsk.com/discoveryfasttrack for details.

Your idea. Our resources.

Does your research have the potential to lead to a new medicine? Are you a

principal investigator affiliated with an academic research institute, college or

university? Would you like to partner with a leading pharmaceutical company

to progress your research towards drug discovery?

If so, the Discovery Fast Track Challenge is for you. Up to ten concepts will be selected.

• GSK will screen your target using our sophisticated lead discovery technologies, such as High Throughput Screening (HTS) and Encoded Library Technologies (ELT)

• Compounds discovered from the screen will provide the basis for further partnership and novel chemical probes to progress your research

• You’ll work directly with a highly skilled team of GSK scientists

• You and your research will be on an accelerated path towards discovery of a new medicine

Fast TrackDiscovery

Challenge

Helpful Tips for Technology Transfer OfficesAbout the submission process.• Useful and specific information for TTOs about the Discovery Fast Track Challenge is available at

www.gsk.com/discoveryfasttrack. Sign up under Challenge News to receive regular updates from the GSK team.

• One-page non-confidential proposals may be submitted directly via the website. As part of this process, investigators are required to supply contact details for the relevant TTO. GSK requires acknowledgement and approval from the TTO prior to initiating the review of Discovery Fast Track proposals. If TTO approval is not subsequently given, proposals will be withdrawn and the information destroyed.

• TTO offices should ideally provide a single contact name for their institution to the GSK administrator at DiscoveryFastTrack@gsk.com so that the TTO can be notified of any submissions from that campus. GSK can provide assistance on how to create a special account for the institutional TTO representative that allows them to see all submissions from their institution.

• Submissions are open from February 24 to April 23 in Europe and from February 24 to May 16 in North America. Please encourage investigators in your institution to submit their proposals as early as possible. In addition, it would be helpful if TTOs review and approve submissions as soon as possible after the above notification from GSK, so that proposals can be moved into the review process in a timely way.

• In case of submissions close to the deadline date, or if the TTO needs more time due to the complexities of a particular submission, GSK has provided a short window after the submission deadline for TTOs to finish their review and provide approval of the submission. If a submission is NOT approved by the TTO within one week of the relevant submission deadline, the submission will be automatically disqualified from the Discovery Fast Track Challenge.

• If a TTO determines that a submission contains confidential information that must be extracted from the proposal in accordance with the challenge rules, a revised proposal should be sent to the GSK administrator at DiscoveryFastTrack@gsk.com by the deadline listed above.

Continued...

Points to bear in mind when reviewing a submission.• Concept and associated material: Are there any existing MTAs with obligations? Are there any associated license

or bailment agreements? Are there any other obligations or restrictions associated with the concept or material (or reagents required to create the materials—such as plasmids, vectors, dyes, etc.)? Can all materials be used by a commercial entity, or are additional licenses required? Is there an existing and related invention case or portfolio that is not conducive to the rules of the challenge? Does the submission contain confidential information that should be removed, e.g. might preclude the university from obtaining patent protection later? Are there any limitations to GSK’s ability to use the materials/target for commercial purposes?

• Submission applicant (and other persons involved in developing the submitted concept): Does their research program funding sources and collaborations (including research awards, MTAs, non-profit awards, collaboration or licensing agreements, visitor agreements for the laboratory, and projects) have overlapping scopes of work and funding with obligations and/or restrictions that would prevent GSK and the investigator from proceeding with the research outlined in the proposal? Are there any third-party obligations (e.g., licensing agreements) that might conflict with the challenge rules and agreements?

GSK

TTOInvestigator

Four possible research outcomes:

Outcome One: GSK and institution agree to continue research under a DPAc agreement to be negotiated; likely research funding available. If no agreement, GSK can elect outcome #3.

Investigators submit online proposals

1

3 GSK notifies finalists and assigns a GSK mentor

4

Finalists submit confidential 3–5 page proposals

6 Finalists visit GSK, present proposals to judging panel

7

Outcome Two: Institution wants to continue research; GSK does not. GSK will provide chemical probes to institution under an agreement or for a (likely) joint publication.

Outcome Three: GSK wants to continue Research; Institution does not. GSK gets a license to patents claiming material in exchange for milestone payments.

Outcome Four: Neither party wants to continue research or no useful chemical probes are identified from the screen. GSK may opt to proceed at a later date after reconsideration and discussion with institution (per MTA).

Challenge opens February 24 in Europe and North America

Milestone

Milestone

Finalists will be asked to present on one of the following dates:Europe – July 7,9,10,11 (Stevenage, UK)North America – September 10,11,12, 15 (Philadelphia, USA)

MilestoneWinners announcedEurope – late-SeptemberNorth America – mid-November

Milestone

Winners notified and screening work-plans designed

9

TTOs confirm approval of proposals by institution

2 CDA signed, MTA discussed with GSK

5

GSK judges review approved proposals and select finalists

GSK judging panel selects successful proposals

8 10 MTA containing work-plans for specific proposals signed

MilestoneFinal deadline for TTO ApprovalEurope – April 30, North America – May 23

Challenge closes Europe – April 23North America – May 16

Screening begins1–2Q 2015

12 Screen outcomes reviewed

Winners announced, team of GSK scientists assigned to project

11

Registration Period & TTO

ApprovalSelection of

FinalistsFinalist

SubmissionSelection of

WinnersWinner MTAs

Signed

Winners Announced, Lab

Work Begins

Screen Outcomes Reviewed

Workflow for Discovery Fast Track ChallengeWorkflow for Discovery Fast Track Challenge

www.gsk.com/discoveryfasttrack